FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122623788> ?p ?o ?g. }

• W2122623788 abstract "Abstract Background Dose escalation and modification of CHOP has improved the prognosis of patients with aggressive lymphoma; even in the rituximab era, dose escalation for high-risk patients is exploited and frequently limited by drug toxicity. Idarubicin (Id) is a 4-demethoxy anthracycline analogue of daunorubicin with activity against lymphoma and has been reported to cause less cardiotoxicity than other anthracylines. The aim of this study was to replace doxorubicine with idarubicin in the CHOEP regimen and to find the maximum tolerable dose (MTD) of idarubicin based on hematotoxicity. Patients and methods Between 11/96 and 09/98, 64 patients (pts) aged 18–75 yrs (pts. 18–60, LDH not elevated, >60 years all risk groups) with newly diagnosed aggressive lymphoma received 6 cycles of CIVEP-14 with an escalating dose of idarubicin, consisting of idarubicin (11–16 mg/m 2 d1) and standard doses of cyclophosphamide, vincristine, etoposide, and prednisone with G-CSF support. Results 55 pts (median age 56 yrs) were evaluable for a final analysis with a median observation time of 9.3 years. The CR-rate was 77.4% ; the 5 and 8-year-EFS rates were 46.4% (95%CI 32.5-60.3%) and 43.5% (29.4-57.6%), respectively, and the 5- and 8 yr OS rates were 64.6% (51.7-77.5%) and 59.9% (46.4-73.4%). 14/55 patients have died due to lymphoma progression, and 2/55 patients (3.6%) due to treatment related toxicity, 4/55 due to other causes (3 infections, 1 acute heart failure). In a matched pair analysis comparing CHOEP-14 and CIVEP-14, CIVEP-14 had a higher hematotoxicity with no significant differences in the event free and overall survival for the two regimens. Conclusions Thus, idarubicin cannot be used instead doxorubicin even if its dose is escalated to achieve similar hematotoxicity. Doxorubicin remains the standard anthracycline for the treatment of aggressive NHL." @default.
• W2122623788 created "2016-06-24" @default.
• W2122623788 creator A5014979722 @default.
• W2122623788 creator A5020918589 @default.
• W2122623788 creator A5026240360 @default.
• W2122623788 creator A5038291686 @default.
• W2122623788 creator A5039483120 @default.
• W2122623788 creator A5054463319 @default.
• W2122623788 creator A5057387418 @default.
• W2122623788 creator A5057766834 @default.
• W2122623788 creator A5066131056 @default.
• W2122623788 creator A5073342980 @default.
• W2122623788 creator A5074209268 @default.
• W2122623788 creator A5088718388 @default.
• W2122623788 creator A5090490279 @default.
• W2122623788 date "2014-01-03" @default.
• W2122623788 modified "2023-10-18" @default.
• W2122623788 title "Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL" @default.
• W2122623788 cites W1492993712 @default.
• W2122623788 cites W1813126099 @default.
• W2122623788 cites W1862918409 @default.
• W2122623788 cites W1912693401 @default.
• W2122623788 cites W1993815556 @default.
• W2122623788 cites W2011512040 @default.
• W2122623788 cites W2050644235 @default.
• W2122623788 cites W2054383376 @default.
• W2122623788 cites W2106459864 @default.
• W2122623788 cites W2108465006 @default.
• W2122623788 cites W2116678763 @default.
• W2122623788 cites W2118935462 @default.
• W2122623788 cites W2126779872 @default.
• W2122623788 cites W2149759073 @default.
• W2122623788 cites W2160305510 @default.
• W2122623788 cites W2167571754 @default.
• W2122623788 cites W2248522132 @default.
• W2122623788 cites W2318772898 @default.
• W2122623788 cites W2465154307 @default.
• W2122623788 doi "https://doi.org/10.1186/2193-1801-3-5" @default.
• W2122623788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3890437" @default.
• W2122623788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24455463" @default.
• W2122623788 hasPublicationYear "2014" @default.
• W2122623788 type Work @default.
• W2122623788 sameAs 2122623788 @default.
• W2122623788 citedByCount "7" @default.
• W2122623788 countsByYear W21226237882014 @default.
• W2122623788 countsByYear W21226237882016 @default.
• W2122623788 countsByYear W21226237882017 @default.
• W2122623788 countsByYear W21226237882018 @default.
• W2122623788 countsByYear W21226237882019 @default.
• W2122623788 countsByYear W21226237882023 @default.
• W2122623788 crossrefType "journal-article" @default.
• W2122623788 hasAuthorship W2122623788A5014979722 @default.
• W2122623788 hasAuthorship W2122623788A5020918589 @default.
• W2122623788 hasAuthorship W2122623788A5026240360 @default.
• W2122623788 hasAuthorship W2122623788A5038291686 @default.
• W2122623788 hasAuthorship W2122623788A5039483120 @default.
• W2122623788 hasAuthorship W2122623788A5054463319 @default.
• W2122623788 hasAuthorship W2122623788A5057387418 @default.
• W2122623788 hasAuthorship W2122623788A5057766834 @default.
• W2122623788 hasAuthorship W2122623788A5066131056 @default.
• W2122623788 hasAuthorship W2122623788A5073342980 @default.
• W2122623788 hasAuthorship W2122623788A5074209268 @default.
• W2122623788 hasAuthorship W2122623788A5088718388 @default.
• W2122623788 hasAuthorship W2122623788A5090490279 @default.
• W2122623788 hasBestOaLocation W21226237881 @default.
• W2122623788 hasConcept C121608353 @default.
• W2122623788 hasConcept C126322002 @default.
• W2122623788 hasConcept C141071460 @default.
• W2122623788 hasConcept C2776694085 @default.
• W2122623788 hasConcept C2776755627 @default.
• W2122623788 hasConcept C2776802502 @default.
• W2122623788 hasConcept C2778720950 @default.
• W2122623788 hasConcept C2779117419 @default.
• W2122623788 hasConcept C2779338263 @default.
• W2122623788 hasConcept C2779429289 @default.
• W2122623788 hasConcept C2781413609 @default.
• W2122623788 hasConcept C3018657049 @default.
• W2122623788 hasConcept C530470458 @default.
• W2122623788 hasConcept C71924100 @default.
• W2122623788 hasConcept C90924648 @default.
• W2122623788 hasConceptScore W2122623788C121608353 @default.
• W2122623788 hasConceptScore W2122623788C126322002 @default.
• W2122623788 hasConceptScore W2122623788C141071460 @default.
• W2122623788 hasConceptScore W2122623788C2776694085 @default.
• W2122623788 hasConceptScore W2122623788C2776755627 @default.
• W2122623788 hasConceptScore W2122623788C2776802502 @default.
• W2122623788 hasConceptScore W2122623788C2778720950 @default.
• W2122623788 hasConceptScore W2122623788C2779117419 @default.
• W2122623788 hasConceptScore W2122623788C2779338263 @default.
• W2122623788 hasConceptScore W2122623788C2779429289 @default.
• W2122623788 hasConceptScore W2122623788C2781413609 @default.
• W2122623788 hasConceptScore W2122623788C3018657049 @default.
• W2122623788 hasConceptScore W2122623788C530470458 @default.
• W2122623788 hasConceptScore W2122623788C71924100 @default.
• W2122623788 hasConceptScore W2122623788C90924648 @default.
• W2122623788 hasIssue "1" @default.
• W2122623788 hasLocation W21226237881 @default.
• W2122623788 hasLocation W21226237882 @default.
• W2122623788 hasLocation W21226237883 @default.
• W2122623788 hasLocation W21226237884 @default.

• next